PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 0.7%
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 0.7%
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Rating) traded down 0.7% during mid-day trading on Wednesday . The stock traded as low as $2.93 and last traded at $2.96. 33,345 shares traded hands during mid-day trading, an increase of 278% from the average session volume of 8,831 shares. The stock had previously closed at $2.98.
Pharmacyte Biotech Inc（OTCMKTS: PMCBD — 获取评级）在周三午盘交易中下跌了0.7％。该股交易价格低至2.93美元，最后一次交易价格为2.96美元。在午盘交易中，有33,345股交易，较8,831股的平均交易量增长了278％。该股此前收于2.98美元。
PharmaCyte Biotech Stock Performance
Pharmacyte Biot
The company's 50 day moving average price is $2.93 and its 200-day moving average price is $2.90.
该公司的50天移动平均价格为2.93美元，其200天移动平均线价格为2.90美元。
About PharmaCyte Biotech
关于 Pharmacyte
(Get Rating)
（获取评分）
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Pharmacyte Biotech, Inc是一家临床阶段的生物技术公司，从事癌症和糖尿病治疗的开发和商业化。它专注于一种名为Cell-in-a-Box的基于纤维素的专有活细胞封装技术，该技术将用作开发无法手术的胰腺癌和其他实体癌肿瘤以及糖尿病治疗的平台。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on PharmaCyte Biotech (PMCBD)
- ASML Reports Massive Growth, Management Points To Sluggish 2023
- Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
- Mullen Automotive: Is The Bloom Off The Rose?
- Diversified Abbott Laboratories Could Reverse And Move Higher
- Okta Reversal In Progress While Catalysts Approach
- 免费获取 StockNews.com 关于 Pharmacyte Biotech（PMCBD）的研究报告的副本
- ASML报告了大规模增长，管理层指出2023年表现疲软
- 分析师 Boost 会让洛克希德·马丁公司的股价上涨、上涨和下跌吗？
- Mullen Automotive：是玫瑰花的吗？
- 多元化的雅培实验室可能会逆转并走高
- 催化剂接近时Okta的逆转正在进行中
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Pharmacyte 生物技术日报的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Pharmacyte Biotech及相关公司的最新新闻和分析师评级的简明每日摘要。
